白细胞介素2对鼻咽癌放、化疗患者机体免疫功能影响的研究

目的 :探讨白细胞介素 2 (IL - 2 )对鼻咽癌 (NPC)患者行放、化疗后免疫功能的影响。方法 :将 90例NPC患者随机平分为局部组 (IL - 2局部用药加放、化疗 )、全身组 (IL - 2静脉滴注加放、化疗 )和常规组 (化疗加放疗 )。另设 30例正常对照组。分别检测免疫治疗前后和放疗结束后患者的免疫功能 ,并与正常组比较。结果 :3组患者的细胞免疫功能治疗前均比对照组低下 (P <0 .0 1) ,体液免疫高亢 ;经 IL - 2治疗后 ,细胞免疫功能有所提高 ,但体液免疫变化不大。放、化疗后 ,全身组和局部组的免疫功能较治疗前变化不明显 ;常规组的细胞免疫功能明显低下 ,体液免疫功能仍无明显变化。结论 :1在放、化疗前 ,小剂量应用 IL - 2治疗对维护和提高 NPC患者的免疫功能有一定的作用 ,全身用药优于局部用药。 2 3种疗法对 NPC患者的体液免疫功能影响不大。

The influeuce of IL-2 on the immunologic function of the NPC patients treated with radiotherapy and chemotherapy

OBJECTIVE: To investigate the combining therapy which not only have cured effect but also can uphold and improve the NPC patient's immunity function after radiotherapy and chemotherapy. METHOD: 90 cases randomly divided into 3 groups 1. Local group (local injected with IL-2 + radiotherapy + chemotherapy); 2. General group (ivdrip with IL-2 + radiotherapy + chemotherapy); 3. Convention group (radiotherapy + chemotherapy). Checked and observed the immunity function around the immunotherapy and after the radiotherapy and chemotherapy. RESULT: Cellular immunity of 3 groups are lower and humoral immunity are hypetuntion than normal person. After treated with IL-2 the cellular immunity improves but there's no great change of the humoral immunity. The immune status of the immune groups have not obvious change than before radiotherapy, at the same time, the cellular immunity of the convention group cut down and the humoral immunity doesn't change obviously. CONCLUSION: 1. It has some effect to uphold and improve the NPC patient's immunity function to treat with small dosage of IL-2 before radiotherapy and chemotherapy, general treatment is better than local injection; 2. The three therapies have not great influence on the patient's humoral immunity.